Background. The serum kinetics of prostate-specific antigen (PSA) after radiation therapy for prostate cancer are not well characterized, and the potential prognostic significance of serum half-lives and of serum doubling times is unclear. This study was designed to address those issues. Methods. O
A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy
β Scribed by Irving D. Kaplan; Richard S. Cox; Malcolm A. Bagshaw
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 496 KB
- Volume
- 68
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND The objective of this study was to assess the biologic activity of rosiglitazone, a peroxisome proliferatorβactivated receptor Ξ³ agonist that has been approved to treat type 2 diabetes, in men with recurrent prostate carcinoma using change in prostate specific antigen (PS
## Background: The authors analyzed retrospectively their institution's experience in treating patients with localized prostate carcinoma with external beam radiation therapy (ebrt) to determine the correlation of various biochemical failure (bf) definitions with clinical failure and cause specific
tients with residual tumor in 1 or more biopsies at 10 -78 months of follow-up Regional Cancer Centre, Ottawa, Ontario, Canwere selected for review. All patients had undergone biopsy on more than one ada. occasion. The 198 biopsies were stained for PSA, high molecular weight keratin,
## Abstract ## BACKGROUND The objective of this report was to present an outcomes validation for the Fox Chase Cancer Center (FCCC) management policy for patients who demonstrate prostate specific antigen (PSA) failure after receiving threeβdimensional conformal radiation therapy (3DCRT). ## METH